David Wohl, MD
Enriched profileProfessor of Medicine, Division of Infectious Diseases · University of North Carolina at Chapel Hill
David Wohl is Professor of Medicine, Division of Infectious Diseases at University of North Carolina at Chapel Hill. OpenAlex indexes 471 publications with 12,001 citations (h-index 57); ClinicalTrials.gov lists 10 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
David Wohl, MD, is Professor of Medicine, Division of Infectious Diseases at University of North Carolina at Chapel Hill, School of Medicine, Division of Infectious Diseases. The public record shows 471 publications with 12,001 citations (h-index 57), centered on HIV. It also documents an investigator role on 10 registered clinical trials, industry payments reported by 9 companies, 13 NIH-funded awards (1997–2026).
- Most recent indexed publication: 2026 · Open forum infectious diseases
- Top research focus: HIV
- 10 registered trials on ClinicalTrials.gov
- Open Payments reporting from 9 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 30 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- Co-author
"HIV and Mass Incarceration: Where Infectious Diseases and Social Justice Meet," North Carolina Medical Journal (2016), argues for reform of HIV criminal laws and addressing drivers of mass incarceration
2016verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hivlawandpolicy.org ↗ - Member
US Department of Health and Human Services (DHHS) Antiretroviral Guidelines Panel, served two terms
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 10 registered studies on ClinicalTrials.gov. The most recent:
- Menopausal HT for Women Living With HIV (HoT)
Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Evaluation of Behavioral Intervention for HIV Positive Prisoners in NC and TX
Sponsor: University of North Carolina, Chapel Hill
- Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation
Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Industry payments
Updated 27 Aug 2026
9 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202530 payments$25,240openpaymentsdata.cms.gov ↗
- Gilead Sciences, Inc.Program year202520 payments$23,765openpaymentsdata.cms.gov ↗
- ViiV Healthcare CompanyProgram year202522 payments$19,145openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
39.5%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor18.9%Tivicay63%Dovato14%Isentress13%Cabenuva7%Juluca4%Part D<11 patientsHuman Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor11%Descovy100%Part D≥18 patientsNervous system
25.7%Opioid Agonist6.1%Oxycodone Hcl52%Methadone Hcl48%Part D<11 patientsGabapentinoids4.7%Gabapentin84%Pregabalin16%Part D<11 patientsCardiovascular
18.6%Statin8.4%Atorvastatin Calcium92%Pravastatin Sodium9%Part D<11 patientsCalcium channel blocker4.3%Amlodipine Besylate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
13 NIH research awards on record, funded 1997–2026 per NIH RePORTER. The latest:
- University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit
Univ of North Carolina Chapel Hill
FY2026$4,869,383UM1AI069423 - The Protective and Pathologic Features of the EVD Survivor Immune System
Univ of North Carolina Chapel Hill
FY2026$690,984R01AI175698 - The Protective and Pathologic Features of the LASV Immune Response (LASV Legacy)
Univ of North Carolina Chapel Hill
FY2026$633,219R01AI190076
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Impact of COVID-19 Monoclonal Antibody Therapy on Subsequent Vaccine-elicited SARS-CoV-2 Immune Responses.
The Journal of infectious diseases
Article2026 - Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial.
Clinical infectious diseases
Clinical Trial2025
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/david-wohl-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Facebook
facebook.com/unchealthcare/posts/unc-health-infectious-disease-expert-dr-david-wohl-was-interviewed-by-wncn-about/1324491806385299
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Instagram
instagram.com/uncdeptmedicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →instagram.com ↗ - Other
en.wikipedia.org/wiki/David_A._Wohl
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →en.wikipedia.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Rutgers Robert Wood Johnson Medical School
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu ↗ - Internal medicine residency
Duke University; Infectious Diseases fellowship, University of North Carolina at Chapel Hill
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu ↗ - Board certified
Internal Medicine and Infectious Disease (ABIM), exact certification years not independently confirmed on a primary UNC page …
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu ↗
- Co-Principal Investigator
Global UNC Infectious Diseases Clinical Trials Unit; Site Leader, Chapel Hill research site
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu ↗ - Site Leader
UNC AIDS Clinical Trials Unit at Chapel Hill
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu ↗
Awards & honors
honors on the public record- Charles van der Horst Humanitarian Award
AIDS Clinical Trials Group (ACTG), inaugural recipient, 2020, recognized for advocacy, research, treatment and care of infectious diseases
2020verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu ↗
Secondary affiliations
appointments beyond the home institution- Member
UNC Center for AIDS Research (CFAR)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu ↗ - Faculty
UNC Institute for Global Health and Infectious Diseases
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →globalhealth.unc.edu ↗ - Faculty member
IAS–USA (International Antiviral Society–USA)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →iasusa.org ↗
Media & interviews
press, podcasts and appearances- Host/featured expert
"The Future of HIV Care", monthly podcast series on TheBodyPro covering HIV prevention, treatment, and services …
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →thebodypro.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu ↗
- HIV PrEP Video Perspectives
expert video commentary series on Healio
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healio.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Lisa Carey, MD
University of North Carolina at Chapel Hill
Robert Sandler, MD
University of North Carolina at Chapel Hill
Diana Perkins, MD
University of North Carolina at Chapel Hill
Hyman Muss, MD
University of North Carolina at Chapel Hill